Literature DB >> 21569843

Fascaplysin exert anti-tumor effects through apoptotic and anti-angiogenesis pathways in sarcoma mice model.

Xiaojun Yan1, Haimin Chen, Xiaoling Lu, Feng Wang, Weifeng Xu, Haixiao Jin, Peng Zhu.   

Abstract

Previous studies indicated that fascaplysin derived from marine sponge can induce tumor cell death by apoptosis and possesses anti-angiogenesis activity. In order to verify these two effects in animal model and to identify action mechanisms, we established a sarcoma mice model, and treated mice with fascaplysin for 10 days. The tumor tissues were examined morphologically and immunohistochemically. The differential gene expression was also investigated by mRNA array. Fascaplysin treatment resulted in a significant suppression of tumor growth. Typical apoptotic phenomena were observed by transmission electron microscope and histological detection. Tissue sections were stained with monoclonal antibody directed to proliferating cell nuclear antigen (PCNA) and CD31. The decreased PCNA and CD31 antigen staining indicate the reduction of tumor cell proliferation and tumor vasculature property of fascaplysin in vivo. Microarrays were used to examine the gene expression profiles of tumors on CapitalBio mouse genome oligo array. The regulated genes analyzed from the expression level showed overlapping gene ontology (GO) categories and pathway mapping. Our findings indicate that cell cycle arrest, apoptosis, regulation of actin cytoskeleton, and cell adhesion all play important roles in the onset of fascaplysin. Detailed analysis by real time PCR of key genes confirmed the experimental results of microarrays. From these findings, it can be considered that fascaplysin can inhibit the growth of S180 cell implanted tumor, and the action mechanisms may involve in apoptosis, anti-angiogenesis, or cell cycle arrest.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21569843     DOI: 10.1016/j.ejps.2011.04.018

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  11 in total

Review 1.  Angiosuppressive properties of marine-derived compounds-a mini review.

Authors:  Patrick Y K Yue; H M Leung; Adela J Li; Tracy N C Chan; T S Lum; Y L Chung; Y H Sung; M H Wong; Kelvin S Y Leung; Eddy Y Zeng
Journal:  Environ Sci Pollut Res Int       Date:  2015-10-31       Impact factor: 4.223

2.  Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.

Authors:  T Mahgoub; A J Eustace; D M Collins; N Walsh; N O'Donovan; J Crown
Journal:  Int J Oncol       Date:  2015-07-21       Impact factor: 5.650

3.  Cytotoxic effects of fascaplysin against small cell lung cancer cell lines.

Authors:  Gerhard Hamilton
Journal:  Mar Drugs       Date:  2014-03-07       Impact factor: 5.118

4.  Anticancer Activity of Fascaplysin against Lung Cancer Cell and Small Cell Lung Cancer Circulating Tumor Cell Lines.

Authors:  Barbara Rath; Maximilian Hochmair; Adelina Plangger; Gerhard Hamilton
Journal:  Mar Drugs       Date:  2018-10-14       Impact factor: 5.118

5.  Total Syntheses and Preliminary Biological Evaluation of Brominated Fascaplysin and Reticulatine Alkaloids and Their Analogues.

Authors:  Maxim E Zhidkov; Polina A Smirnova; Oleg A Tryapkin; Alexey V Kantemirov; Yuliya V Khudyakova; Olesya S Malyarenko; Svetlana P Ermakova; Valeria P Grigorchuk; Moritz Kaune; Gunhild von Amsberg; Sergey A Dyshlovoy
Journal:  Mar Drugs       Date:  2019-08-25       Impact factor: 5.118

6.  Cyclin-dependent kinase 4 phosphorylates and positively regulates PAX3-FOXO1 in human alveolar rhabdomyosarcoma cells.

Authors:  Lingling Liu; Jing Wu; Su Sien Ong; Taosheng Chen
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

Review 7.  Marine-derived angiogenesis inhibitors for cancer therapy.

Authors:  Ying-Qing Wang; Ze-Hong Miao
Journal:  Mar Drugs       Date:  2013-03-15       Impact factor: 5.118

8.  The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic Activity.

Authors:  Emmanuel Ampofo; Thomas Später; Isabelle Müller; Hermann Eichler; Michael D Menger; Matthias W Laschke
Journal:  Mar Drugs       Date:  2015-11-09       Impact factor: 5.118

9.  Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1α and Inhibition of VEGFR2 and TRKA.

Authors:  Taek-In Oh; Yoon-Mi Lee; Taek-Jin Nam; Young-San Ko; Shinmee Mah; Jinhee Kim; Younghoon Kim; Rallabandi Harikrishna Reddy; Young Jun Kim; Sungwoo Hong; Ji-Hong Lim
Journal:  Int J Mol Sci       Date:  2017-09-29       Impact factor: 5.923

Review 10.  A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2011.

Authors:  Wamtinga Richard Sawadogo; Marc Schumacher; Marie-Hélène Teiten; Claudia Cerella; Mario Dicato; Marc Diederich
Journal:  Molecules       Date:  2013-03-25       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.